Qurient’s Mocaciclib Opens New Combination Frontiers for Hard-to-Treat Breast Cancer
Qurient announced on June 29 that it presented key clinical data highlighting the mechanistic advantages of its CDK7-inhibiting oncology candidate,...
Search results for "Phase 3 clinical trial"
Target the Core: Why 'Deep Remission' Is the New Gold Standard in Inflammatory Bowel Disease Treatment
Treatment for inflammatory bowel disease is rapidly moving beyond simple symptom management toward the structural restoration of the intestinal...
Resetting the Body Clock: Smartphone App Cuts Mood Disorder Relapse Rates to One-Third
"I’m taking my medication faithfully—so why is this happening again?"It is a deeply frustrating question that patients...
When Other Biologics Fail: Skyrizi Drives Steroid-Free Remission in Over Half of Hard-to-Treat Crohn’s Patients
Crohn’s disease remains one of the most challenging inflammatory bowel diseases to manage.
From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’
The standard of care in cancer treatment is undergoing a rapid paradigm shift. For decades, the default oncological...
Seoul National University Hospital to Lead 30 Billion Won Bidirectional Brain-to-Robot BCI Clinical Trials
The idea of walking by thought alone—and even regaining sensations in the soles of the feet—is edging closer to reality.
Curocell’s Homegrown CAR-T Therapy Rimqarto Lands Spotlight in Top Hematology Journal Blood
Curocell, a South Korean clinical-stage biotech company specializing in chimeric antigen receptor T-cell (CAR-T)...
RNA Therapy Emerges as Critical Fast-Track for Cholesterol Control After Heart Attacks
Myocardial infarction and unstable angina are life-threatening medical emergencies that occur when the blood vessels...
Celltrion Advances Next-Generation Immuno-Oncology Candidate with Strong Preclinical Results
Celltrion has announced promising preclinical data for its investigational immuno-oncology candidate, CT-P72/ABP-102,...
FDA Grants Streamlined Path for MediPost’s Cartistem, Slashing U.S. Trial Burden
The U.S. Food and Drug Administration has agreed to a significantly streamlined clinical path for Cartistem, a landmark...